Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.77 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.77 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.77 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.77 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.49 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | HTR3B | O95264 | 1/20 | 0.49 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.49 |
| ▸ | CHRNG | P07510 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16707758 | 0.88 | CHRNB2 (0.67) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL8679467 | 0.87 | CHRNB2 (0.61) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL7934551 | 0.87 | CHRNB2 (0.61) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13238778 | 0.87 | CHRNB2 (1.00) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL155935 | 0.87 | CHRNB2 (1.00) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL15836592 | 0.87 | CHRNB2 (1.00) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL16130578 | 0.85 | CHRNB2 (0.89) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2606118 | 0.85 | CHRNB2 (0.89) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL16130558 | 0.85 | CHRNB2 (0.89) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL21599188 | 0.85 | CHRNB2 (0.62) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105705489-B | Compound as immunomodulator | 百时美施贵宝公司 | 2019-04-26 | — | — | CN | claimed |
| CN-105705489-A | Compounds useful as immunomodulators | 百时美施贵宝公司 | 2016-06-22 | — | — | CN | claimed |
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023107648-A2 | SYNTHESIS OF ESTER, CARBONATE, AND CARBAMATE-DERIVED NOVEL BIODEGRADABLE IONIZABLE LIPIDS FROM METHYL RICINOLEATE OR METHYL 12-HYDROXYSTEARATE AND ITS APPLICATIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023064585-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELTION PHARMACEUTICALS LTD (CH) | 2021-12-23 | — | — | US | disclosed |
| US-11136317-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2021-10-05 | — | — | US | disclosed |
| US-20210277020-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-09-09 | — | — | US | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-3310767-B1 | 2,5-DISUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AS NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-07-22 | — | — | EP | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110301355-A1 | Amidine compounds and herbicides | NIPPON SODA CO., LTD. (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110166122-A1 | SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2011-07-07 | — | — | US | disclosed |
| WO-2011021726-A2 | NITROGEN-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011006074-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010048314-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010033941-A1 | SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| CN-1802351-A | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK & CO INC (US) | 2006-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277020-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | CHRNB2 4415/4885CHRNA7 4522/4885CHRNA4 4613/4885 |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | PDXK, DTYMK, TNNI3K | CHRNB2 2211/4885CHRNA7 1663/4885CHRNA4 1692/4885 |
| US-11690915-B2 | Ras inhibitors | KRAS, NRAS, HRAS | CHRNB2 4838/4885CHRNA7 4871/4885CHRNA4 4878/4885 |
| US-20110301355-A1 | Amidine compounds and herbicides | DDT, GATD3, PAM | CHRNB2 1487/4885CHRNA7 1410/4885CHRNA4 1187/4885 |
| US-20110166122-A1 | SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | NTRK1, NTRK3, NTRK2 | CHRNB2 796/4885CHRNA7 855/4885CHRNA4 806/4885 |
| US-20230226186-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CHRNB2 4838/4885CHRNA7 4871/4885CHRNA4 4878/4885 |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | FRK, TXK, TNNI3K | CHRNB2 1521/4885CHRNA7 1061/4885CHRNA4 1125/4885 |
| US-11136317-B2 | NADPH oxidase 4 inhibitors | NOX4, NOX1, CYBB | CHRNB2 2690/4885CHRNA7 2942/4885CHRNA4 1753/4885 |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | CHRNB2 2690/4885CHRNA7 2942/4885CHRNA4 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.